ERBB2 and breast carcinoma: Several in vitro studies have indicated that while T-DM1 combined with radiotherapy enhances radiosensitivity in HER-2-positive esophageal cancer and gastric cancer, it does not sensitize breast cancer cells to radiation, although a strictly additive effect is observed [27–29].